Table 2.
Triterpene | Tumour cells | Action | Molecular Structure | Target | Ref. | |
---|---|---|---|---|---|---|
Ganoderic acid (3α,22β-diacetoxy-7α-hydroxyl-5α-lanost-8,24-E-dien-26-oic acid) | in vitro | Lung:95D Cervical: HeLa |
cytotoxic | [36] | ||
Ganoderic acid Mk | in vitro | Lung:95D Cervical: HeLa |
cytotoxic | [36] | ||
Ganoderic acid S | Lung:95D Cervical: HeLa |
cytotoxic | [36] | |||
Ganoderic acid Mf | Lung:95D Cervical: HeLa |
cytotoxic | [36] | |||
Ganoderic acid R | Lung:95D Cervical: HeLa |
Cytotoxic | [36] | |||
Ganoderic acid Mc | Lung:95D Cervical: HeLa |
Cytotoxic | [36] | |||
Ganoderic acid A | Breast: MDA-MB-231 | Inhibited growth and invasive behaviour of breast cancer cells | AP-1 or NF-κB | [44] | ||
Ganoderic acid F | Breast: MDA-MB-231 | Ineffective | AP-1 NF-κB uPA Cdk4 |
[44] | ||
Ganoderic acid H | Breast: MDA-MB-231 | Inhibited growth and invasive behaviour of breast cancer cells | AP-1 NF-κB uPA Cdk4 |
[44] | ||
ganoderic acid X | in vitro | Liver: HuH-7 Colon: HCT-116 |
Inhibits topoisomerases and induces apoptosis of cancer cells | ERK, JNK | [41] | |
ganoderic acid T | in vitro | lung: 95D liver: SMMC7721 epidermis: KB-A-1 and KB-3-1 cervix: HeLa |
Decrease in proliferation of some cancer cells. Strongly inhibits the formation of cell colony of 95-D. | p53 Bax caspase-8 |
[40] | |
in vitro | colon: HCT-116 | Inhibits proliferation | NFκB-α, MMP-9, uPA, iNOS | [45] | ||
in vitro | melanoma: A375 colon: Ls174t |
Inhibits growth | MMP2/9 NF-κB |
[51] | ||
in vivo | Lung: LLC | Suppresses tumour growth and LLC metastasis | MMP 2/9 | [45] | ||
ganoderic acid Me | in vitro | Colon: HCT-116 HCT-8 |
Possesses cytotoxicity | p53 Bax |
[52,53] | |
in vitro | Lung: 95-D | inhibits cancer cell invasion | MMP 2/9 | [46] | ||
in vitro in vivo |
Breast: MDA-MB-231 | inhibits proliferation and invasion and induces apoptosis | NF-κB, TNF-α, VEGF, IL-6/8, MMP-9, Bcl-2, c-Myc and CCND1 | [54] | ||
ganoderic acid D | in vitro | Cervical: HeLa | inhibits proliferation | AHA1 Cytokeratin 19 Cytokeratin 1 PRDX3 |
[55] | |
ganoderic acid E | in vitro | Liver: Hep G2 Hep G2,2,15 |
cytotoxic | [56] | ||
ganoderic acid DM | in vitro | Prostate: PC-3, LnCaP | inhibits prostate cancer cell proliferation and metastasis | MMP-2 MMP-9 IL-1, IL-6, TNF-α, and CCL-2/MCP-1 |
[48] | |
lucidenic acid A | leukaemia: HL 60 | decreases cell population growth, cell cycle arrest | Bcl-2 caspase-9 caspase-3 |
[49] | ||
lucidenic acid B | leukaemia: HL 60 | Induces apoptosis | Bcl-2 caspase-9 caspase-3 |
[49,57] | ||
liver: HepG2 Lymphoma: CA46 |
MMP-9, NF-κB, ERK1/2, AP-1, c-Jun, c-Fos |
|||||
lucidenic acid C | leukaemia: HL 60 | decreases cell population growth, cell cycle arrest | Bcl-2 caspase-9 caspase-3 |
[49] | ||
lucidenic acid N | leukaemia: HL 60 | decreases cell population growth, cell cycle arrest | Bcl-2 caspase-9 caspase-3 |
[49] | ||
Ganoderiol F | in vitro | Lung: LLC Meth A, sarcoma: Sarcoma-180 Carcinoma: T-47D |
Cytotoxicity | [58] | ||
in vivo | Lung: LLC | inhibitory effect on tumour growth | [50] | |||
Ganodermanontriol | Colon: HCT-116, HT-29 | Inhibition of cell proliferation | β-catenin, cyclin-D1, Cdk4, PCNA, E-cadherin |
[59] | ||
Breast: MDA-MB-231 | uPA, uPAR |